Advanced

Translational platelet research in patients with coronary artery disease: hat are the rnalor knowledge gaps?

Gurbel, Paul A.; Roe, Matthew T.; Jakubowski, Joseph A.; Shah, Svathi; Erlinge, David LU ; Goodman, Shaun G.; Huber, Kurt; Chan, Mark Y.; Cornel, Jan H. and Tantry, Udaya S., et al. (2012) In Thrombosis and Haemostasis 108(1). p.12-20
Abstract
Translational platelet function investigations performed in the percutaneous coronary intervention (PCI)-treated population receiving clopidogrel have identified high platelet reactivity to ADP (HPR) as a major risk factor for both acute as well as long-term ischaemic event occurrence, including stent thrombosis. Recent studies have highlighted the relation of single nucleotide polymorphisms of genes involved in clopidogrel absorption and metabolism to reduced pharmacokinetic and pharmacodynamic responses to clopidogrel. CYP2C19 loss-of-function (LoF) allele carriage has been associated with increased thrombotic risk in the PCI population. However, there is no information regarding the utility of platelet function testing to predict... (More)
Translational platelet function investigations performed in the percutaneous coronary intervention (PCI)-treated population receiving clopidogrel have identified high platelet reactivity to ADP (HPR) as a major risk factor for both acute as well as long-term ischaemic event occurrence, including stent thrombosis. Recent studies have highlighted the relation of single nucleotide polymorphisms of genes involved in clopidogrel absorption and metabolism to reduced pharmacokinetic and pharmacodynamic responses to clopidogrel. CYP2C19 loss-of-function (LoF) allele carriage has been associated with increased thrombotic risk in the PCI population. However, there is no information regarding the utility of platelet function testing to predict outcomes in patients with stable coronary artery disease and in medically managed patients with acute coronary syndromes. Additionally, few studies have included longitudinal assessment of platelet function to assess a potential time-dependent relation to ischaemic event occurrence and no phase-III antiplatelet-therapy trial has included a large enough platelet function sub-study to examine the relation between on-treatment platelet reactivity, bleeding, and ischaemic event occurrence. Therefore, futher studies are needed to delineate the role of platelet function testing across the spectrum of symptomatic coronary artery disease. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
ADP receptors, clinical trials, antiplatelet drugs, platelet, pharmacology, coronary syndrome
in
Thrombosis and Haemostasis
volume
108
issue
1
pages
12 - 20
publisher
F K Schattauer Verlag Gmbh
external identifiers
  • wos:000306538400006
  • scopus:84863646547
ISSN
0340-6245
DOI
10.1160/TH12-01-0039
language
English
LU publication?
yes
id
583d315e-97a9-42ca-afc7-d0a569800561 (old id 2979352)
date added to LUP
2012-09-03 07:16:19
date last changed
2017-07-09 04:04:15
@article{583d315e-97a9-42ca-afc7-d0a569800561,
  abstract     = {Translational platelet function investigations performed in the percutaneous coronary intervention (PCI)-treated population receiving clopidogrel have identified high platelet reactivity to ADP (HPR) as a major risk factor for both acute as well as long-term ischaemic event occurrence, including stent thrombosis. Recent studies have highlighted the relation of single nucleotide polymorphisms of genes involved in clopidogrel absorption and metabolism to reduced pharmacokinetic and pharmacodynamic responses to clopidogrel. CYP2C19 loss-of-function (LoF) allele carriage has been associated with increased thrombotic risk in the PCI population. However, there is no information regarding the utility of platelet function testing to predict outcomes in patients with stable coronary artery disease and in medically managed patients with acute coronary syndromes. Additionally, few studies have included longitudinal assessment of platelet function to assess a potential time-dependent relation to ischaemic event occurrence and no phase-III antiplatelet-therapy trial has included a large enough platelet function sub-study to examine the relation between on-treatment platelet reactivity, bleeding, and ischaemic event occurrence. Therefore, futher studies are needed to delineate the role of platelet function testing across the spectrum of symptomatic coronary artery disease.},
  author       = {Gurbel, Paul A. and Roe, Matthew T. and Jakubowski, Joseph A. and Shah, Svathi and Erlinge, David and Goodman, Shaun G. and Huber, Kurt and Chan, Mark Y. and Cornel, Jan H. and Tantry, Udaya S. and Ohman, E. Magnus},
  issn         = {0340-6245},
  keyword      = {ADP receptors,clinical trials,antiplatelet drugs,platelet,pharmacology,coronary syndrome},
  language     = {eng},
  number       = {1},
  pages        = {12--20},
  publisher    = {F K Schattauer Verlag Gmbh},
  series       = {Thrombosis and Haemostasis},
  title        = {Translational platelet research in patients with coronary artery disease: hat are the rnalor knowledge gaps?},
  url          = {http://dx.doi.org/10.1160/TH12-01-0039},
  volume       = {108},
  year         = {2012},
}